These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 15965261)

  • 1. A Drosophila model of multiple endocrine neoplasia type 2.
    Read RD; Goodfellow PJ; Mardis ER; Novak N; Armstrong JR; Cagan RL
    Genetics; 2005 Nov; 171(3):1057-81. PubMed ID: 15965261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model for GFR alpha 4 function and a potential modifying role in multiple endocrine neoplasia 2.
    Vanhorne JB; Andrew SD; Harrison KJ; Taylor SA; Thomas B; McDonald TJ; Ainsworth PJ; Mulligan LM
    Oncogene; 2005 Feb; 24(6):1091-7. PubMed ID: 15592530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drosophila as a novel therapeutic discovery tool for thyroid cancer.
    Das T; Cagan R
    Thyroid; 2010 Jul; 20(7):689-95. PubMed ID: 20578898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation.
    Hickey JG; Myers SM; Tian X; Zhu SJ; V Shaw JL; Andrew SD; Richardson DS; Brettschneider J; Mulligan LM
    Genes Chromosomes Cancer; 2009 May; 48(5):429-40. PubMed ID: 19226610
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Poon CLC; Brumby AM; Richardson HE
    Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29861494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
    Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
    Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.
    de Groot JW; Links TP; Plukker JT; Lips CJ; Hofstra RM
    Endocr Rev; 2006 Aug; 27(5):535-60. PubMed ID: 16849421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations.
    Margraf RL; Crockett DK; Krautscheid PM; Seamons R; Calderon FR; Wittwer CT; Mao R
    Hum Mutat; 2009 Apr; 30(4):548-56. PubMed ID: 19177457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.
    Latteyer S; Klein-Hitpass L; Khandanpour C; Zwanziger D; Poeppel TD; Schmid KW; Führer D; Moeller LC
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1016-22. PubMed ID: 26765577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease.
    Arighi E; Popsueva A; Degl'Innocenti D; Borrello MG; Carniti C; Perälä NM; Pierotti MA; Sariola H
    Mol Endocrinol; 2004 Apr; 18(4):1004-17. PubMed ID: 14715928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular advances in medullary thyroid cancer diagnostics.
    Hubner RA; Houlston RS
    Clin Chim Acta; 2006 Aug; 370(1-2):2-8. PubMed ID: 16519882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromes.
    Zupan A; Glavač D
    Exp Mol Pathol; 2015 Dec; 99(3):416-25. PubMed ID: 26321248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
    Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and function of RET in multiple endocrine neoplasia type 2.
    Plaza-Menacho I
    Endocr Relat Cancer; 2018 Feb; 25(2):T79-T90. PubMed ID: 29175871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple endocrine neoplasia type 2.
    Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Tognarini I; Luzi E; Brandi ML
    Orphanet J Rare Dis; 2006 Nov; 1():45. PubMed ID: 17105651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mouse soluble GFRalpha4 receptor activates RET independently of its ligand persephin.
    Yang J; Runeberg-Roos P; Leppänen VM; Saarma M
    Oncogene; 2007 May; 26(26):3892-8. PubMed ID: 17213820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2).
    Jimenez C; Gagel RF
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S150-7. PubMed ID: 15135800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.
    Gujral TS; Mulligan LM
    Ann N Y Acad Sci; 2006 Aug; 1073():234-40. PubMed ID: 17102091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts in RET-related genetics, signaling and therapeutics.
    Plaza-Menacho I; Burzynski GM; de Groot JW; Eggen BJ; Hofstra RM
    Trends Genet; 2006 Nov; 22(11):627-36. PubMed ID: 16979782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.